Our UK-wide ovarian cancer research programme is closed for new applications. For proposals under consideration in the current round, please see our application timetable.
Translational Research Awards
New targeted treatments and optimising existing treatments
What we're looking for
We're looking for projects that will optimise and develop more effective and less toxic treatments for ovarian cancer, with a special focus on treatments that will improve overall survival. These awards aren't designed for basic or early discovery studies.
Many important challenges need to be overcome to improve treatments for patients, for example we need to:
- Identify new drug targets within subtypes of ovarian cancer and develop new targeted treatments
- Understand why tumours develop resistance to therapies, developing strategies to prevent and overcome resistance
- Develop new immunologic approaches to treating ovarian cancer
- Understand the effectiveness of existing drugs against different tumour subtypes
- Understand the effectiveness of specific drug combinations in subtypes
- Research to predict which patients will benefit from chemotherapy
- Develop appropriate treatments for older patients
- Identify prognostic markers that indicate response to treatment
- Develop robust surgical trials to validate new technologies and optimise treatments
While these are some areas that need research, we'll consider support for any research of relevance to optimising or developing new treatments. For further information about our priorities, read our research strategy.
- The principal investigator must be from a UK university, hospital, clinical trials unit or a research institute affiliated to one of these organisations.
- The principal investigator must be resident in the UK, and the project and employment must also take place in the UK.
- We particularly encourage applications from early career researchers, who may apply with a more senior co-applicant from the same institution who holds a permanent position. Both applicants must already hold salaried positions covering the duration of the project. The role of the senior co-applicant – in relation to the project – should be explained.
- The award can't be used to fund principal or co-investigator salaries.
- The award can't be used to fund a PhD student.
- The award can be used for projects with or without associated salary costs.
- The award can be used for joint funding larger projects providing our standard conditions of grant aren't breached.
- Applications will be judged on scientific merit and compliance with our published research strategy.
What we offer
- The maximum period of support is 36 months.
- The maximum value of this grant is £200,000.
- Payment will be quarterly, in arrears.
- No variation (virement) between budget headings is allowed without Target Ovarian Cancer's approval.
- This award isn't intended for major equipment and no equipment over £5,000 will be funded.
- We require the project to start within three months of the proposed start date. Please be realistic with your start date (allow time for ethics, recruitment etc).
- 10 per cent of the grant value will be withheld until both end of grant research and finance reports are received by Target Ovarian Cancer.
- We require research updates every six months, detailing progress against research milestones outlined in the original application.
- On average, our grant funding success rate is 18 per cent of all full applications received and 8 per cent of all preliminary applications received.
- April 2021: Call for outline proposals opens
- 28 May 2021 (12pm): Closing date for submission of outline proposals
- 10 June 2021: Full proposals invited from shortlisted applications
- 20 August 2021: Deadline for submitting full proposals
- End November 2021: Successful applicant(s) informed
How to apply
Applications are considered once a year. Our programme is closed for new applications and we expect the next round to be in 2022.